HK1120556A1 - Neurotrophic factors - Google Patents

Neurotrophic factors

Info

Publication number
HK1120556A1
HK1120556A1 HK08113487.5A HK08113487A HK1120556A1 HK 1120556 A1 HK1120556 A1 HK 1120556A1 HK 08113487 A HK08113487 A HK 08113487A HK 1120556 A1 HK1120556 A1 HK 1120556A1
Authority
HK
Hong Kong
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
HK08113487.5A
Other languages
English (en)
Inventor
Dinah Wen Yee Sah
Teit E Johansen
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Publication of HK1120556A1 publication Critical patent/HK1120556A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
HK08113487.5A 2001-03-12 2008-12-11 Neurotrophic factors HK1120556A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
HK1120556A1 true HK1120556A1 (en) 2009-04-03

Family

ID=25189406

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113487.5A HK1120556A1 (en) 2001-03-12 2008-12-11 Neurotrophic factors

Country Status (16)

Country Link
US (1) US20020055467A1 (es)
EP (2) EP1373503B1 (es)
JP (2) JP3738008B2 (es)
CN (1) CN1268744C (es)
AT (2) ATE509103T1 (es)
AU (1) AU2002240943B2 (es)
CA (1) CA2440767C (es)
CY (1) CY1111750T1 (es)
DE (1) DE60223511T2 (es)
DK (2) DK1373503T3 (es)
ES (2) ES2296899T3 (es)
HK (1) HK1120556A1 (es)
NZ (1) NZ528790A (es)
PT (2) PT1373503E (es)
SI (2) SI1373503T1 (es)
WO (1) WO2002072826A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
BR9912819A (pt) * 1998-07-14 2001-05-02 Janssen Pharmaceutica Nv Fator de crescimento neurotrófico
CN1547483A (zh) * 2000-12-22 2004-11-17 �����ɷ� Artemin-gdnf配体家族的一个成员的新用途
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2002078730A2 (en) * 2001-03-28 2002-10-10 Biogen, Inc. Use of neublastin polypeptides for treating neuropathic pain
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1594436B1 (en) * 2003-01-31 2010-08-25 Biogen Idec MA Inc. Mutated neublastin
CA2864810A1 (en) * 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
AU2004245175C1 (en) 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
CA2577755C (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
CN101123978B (zh) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
AU2011307488B2 (en) * 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛
CN117279657A (zh) 2021-05-18 2023-12-22 日本株式会社Ltt生物医药 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
WO1997044356A2 (en) 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
ES2287020T3 (es) * 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.

Also Published As

Publication number Publication date
EP1373503B1 (en) 2007-11-14
SI1930439T1 (sl) 2011-09-30
WO2002072826A3 (en) 2003-04-10
ATE378353T1 (de) 2007-11-15
EP1930439B1 (en) 2011-05-11
ES2366610T3 (es) 2011-10-21
DE60223511D1 (de) 2007-12-27
CY1111750T1 (el) 2015-10-07
DK1930439T3 (da) 2011-08-29
JP2005198656A (ja) 2005-07-28
JP2004531242A (ja) 2004-10-14
DE60223511T2 (de) 2008-10-23
AU2002240943A2 (en) 2002-09-24
CA2440767C (en) 2012-05-29
CN1509333A (zh) 2004-06-30
CN1268744C (zh) 2006-08-09
NZ528790A (en) 2004-06-25
US20020055467A1 (en) 2002-05-09
CA2440767A1 (en) 2002-09-19
JP3738008B2 (ja) 2006-01-25
ATE509103T1 (de) 2011-05-15
PT1373503E (pt) 2008-02-26
EP1930439A1 (en) 2008-06-11
DK1373503T3 (da) 2008-03-25
EP1373503A2 (en) 2004-01-02
AU2002240943B2 (en) 2007-05-10
ES2296899T3 (es) 2008-05-01
WO2002072826A2 (en) 2002-09-19
PT1930439E (pt) 2011-07-25
SI1373503T1 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
HK1120556A1 (en) Neurotrophic factors
SI1095140T1 (sl) Nevrotrofični dejavniki
IL161016A (en) Polypeptides capable of ang-2 binding
PT1015585E (pt) Homologos de ligandos de tie
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2007045019A3 (en) Polyoleosins
WO2003080795A8 (en) Novel nucleic acids and secreted polypeptides
WO2003025142A3 (en) Novel nucleic acids and secreted polypeptides
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
EA200100110A1 (ru) Нейротрофические факторы
WO2001021794A3 (en) Smad associating polypeptides
WO2001057187A3 (en) Novel bone marrow nucleic acids and polypeptides
WO2001088091A3 (en) Novel bone marrow nucleic acids and polypeptides
TW200519206A (en) Methods for producing novel medaka and novel medaka
WO2004039319A3 (en) Novel human polypeptides encoded by polynucleotides

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM BIOGEN IDEC MA, INC. TO BIOGEN IDEC MA INC..

Effective date: 20111025

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160312